50% off Premium Yearly

NASDAQ:SBRA
This summary was created by AI, based on 1 opinions in the last 12 months.
Sabra Health Care REIT is emerging as a strong investment choice for 2026, ranked as a top pick by experts. The company is currently trading at a remarkably attractive price-to-FFO ratio of 12x, which is significantly lower than the broader market's average, and boasts a solid dividend yield of 6.5%. Their operations are primarily focused on nursing, retirement, and behavioral health sectors, which are benefiting from favorable demographic trends. Anticipated earnings growth of 5.5% this year, combined with a 17% increase in stock price over the last year, indicates both momentum and robust fundamentals. Moreover, unlike many sectors facing threats from technological advancements like AI, Sabra appears well-positioned to leverage these changes to their advantage.
Sabra Health Care REIT is a American stock, trading under the symbol SBRA (previously SBRA-Q on Stockchase) on the NASDAQ (SBRA). It is usually referred to as NASDAQ:SBRA or SBRA
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on SBRA (previously SBRA-Q on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Sabra Health Care REIT.
Sabra Health Care REIT was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Sabra Health Care REIT.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Sabra Health Care REIT.
Sabra Health Care REIT is followed by 6 investors on Stockchase and is a trending stock that is worth watching.
On 2026-06-17, Sabra Health Care REIT (SBRA) stock closed at a price of $18.05.
Her top pick of 2026. Trades at 12x FFO, half the market's, and pays a 6.5% dividend. They are in the nursing space (retirement and skilled), and behavioural health. Enjoys demographic winds. Earnings to grow 5.5% this year. Up 17% last year, so has momentum as well as fundamentals. Is not threatened by AI, and could even benefit Sabra.